{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:31:40Z","timestamp":1782901900911,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"Taiwan Ministry of Science and Technology","doi-asserted-by":"publisher","award":["112\\u20132628-B-002 -029 -MY3"],"award-info":[{"award-number":["112\\u20132628-B-002 -029 -MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ijcard.2024.132198","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T16:02:02Z","timestamp":1716307322000},"page":"132198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The effect of antiarrhythmic medications on the risk of cardiovascular outcomes in patients with atrial fibrillation and coronary artery disease"],"prefix":"10.1016","volume":"409","author":[{"given":"Shih-Rong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Chih","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Tse","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Lin","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Kai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijcard.2024.132198_bb0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","article-title":"Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights","volume":"127","author":"Kornej","year":"2020","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.ijcard.2024.132198_bb0010","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ijcard.2024.132198_bb0015","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcard.2024.132198_bb0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"issue":"14","key":"10.1016\/j.ijcard.2024.132198_bb0025","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.132198_bb0030","doi-asserted-by":"crossref","unstructured":"Proietti M, Vitolo M, Harrison SL, Lane DA, Fauchier L, Marin F, et al. Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF long-term general registry. Clin. Res. Cardiol. 2022;111(1):70\u201384.","DOI":"10.1007\/s00392-021-01914-y"},{"issue":"10053","key":"10.1016\/j.ijcard.2024.132198_bb0035","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"issue":"38","key":"10.1016\/j.ijcard.2024.132198_bb0040","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.ijcard.2024.132198_bb0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tcm.2022.09.006","article-title":"The relationship between atrial fibrillation and coronary artery disease: understanding common denominators","volume":"34","author":"Mekhael","year":"2024","journal-title":"Trends Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132198_bb0050","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1152\/ajpheart.00702.2020","article-title":"Coronary heart disease and atrial fibrillation: a vicious cycle","volume":"320","author":"Liang","year":"2021","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"4","key":"10.1016\/j.ijcard.2024.132198_bb0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0002-9149(91)90828-9","article-title":"Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter","volume":"68","author":"Crijns","year":"1991","journal-title":"Am. J. Cardiol."},{"issue":"7","key":"10.1016\/j.ijcard.2024.132198_bb0060","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMoa0803778","article-title":"Effect of dronedarone on cardiovascular events in atrial fibrillation","volume":"360","author":"Hohnloser","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"7016","key":"10.1016\/j.ijcard.2024.132198_bb0065","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1136\/bmj.311.7016.1361","article-title":"ABC of atrial fibrillation. History, epidemiology, and importance of atrial fibrillation","volume":"311","author":"Lip","year":"1995","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.ijcard.2024.132198_bb0070","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2019.02.080","article-title":"Antithrombotics: from aspirin to DOACs in coronary artery disease and atrial fibrillation (part 3\/5)","volume":"74","author":"Verheugt","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.ijcard.2024.132198_bb0075","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial","volume":"324","author":"Echt","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijcard.2024.132198_bb0080","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0002-9149(96)00332-3","article-title":"Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone multicenter study group","volume":"78","author":"Podrid","year":"1996","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2024.132198_bb0085","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0735-1097(92)90003-6","article-title":"Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The stroke prevention in atrial fibrillation investigators","volume":"20","author":"Flaker","year":"1992","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2024.132198_bb0090","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023838","article-title":"AIM-AF: a physician survey in the United States and Europe","volume":"11","author":"Camm","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132198_bb0095","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.hrthm.2014.08.037","article-title":"Amiodarone use and risk of acute pancreatitis: a population-based case-control study","volume":"12","author":"Lai","year":"2015","journal-title":"Heart Rhythm."},{"issue":"7","key":"10.1016\/j.ijcard.2024.132198_bb0100","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.amjmed.2004.11.028","article-title":"Amiodarone and the thyroid","volume":"118","author":"Basaria","year":"2005","journal-title":"Am. J. Med."},{"issue":"11","key":"10.1016\/j.ijcard.2024.132198_bb0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.JAA.0000524713.17719.c8","article-title":"Amiodarone-induced pulmonary toxicity","volume":"30","author":"Colby","year":"2017","journal-title":"JAAPA"},{"issue":"23","key":"10.1016\/j.ijcard.2024.132198_bb0110","doi-asserted-by":"crossref","first-page":"11347","DOI":"10.18632\/aging.102532","article-title":"Risk of ischemic stroke in patients with hypertrophic cardiomyopathy in the absence of atrial fibrillation - a nationwide cohort study","volume":"11","author":"Lin","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"12","key":"10.1016\/j.ijcard.2024.132198_bb0115","first-page":"1764","article-title":"Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation","volume":"21","author":"Boriani","year":"2019","journal-title":"Europace"},{"issue":"9","key":"10.1016\/j.ijcard.2024.132198_bb0120","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jfma.2021.12.024","article-title":"Quality assurance of integrative big data for medical research within a multihospital system","volume":"121","author":"Lee","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"issue":"5","key":"10.1016\/j.ijcard.2024.132198_bb0125","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/resp.12312","article-title":"Introduction to propensity scores","volume":"19","author":"Williamson","year":"2014","journal-title":"Respirology"},{"issue":"28","key":"10.1016\/j.ijcard.2024.132198_bb0130","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat. Med."},{"issue":"3","key":"10.1016\/j.ijcard.2024.132198_bb0135","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/EDE.0000000000000627","article-title":"Matching weights to simultaneously compare three treatment groups: comparison to three-way matching","volume":"28","author":"Yoshida","year":"2017","journal-title":"Epidemiology"},{"issue":"6","key":"10.1016\/j.ijcard.2024.132198_bb0140","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/europace\/euab262","article-title":"International cohort study on the effectiveness of dronedarone and other antiarrhythmic drugs for atrial fibrillation in real-world practice (EFFECT-AF)","volume":"24","author":"Khachatryan","year":"2022","journal-title":"Europace"},{"issue":"4","key":"10.1016\/j.ijcard.2024.132198_bb0145","first-page":"890","article-title":"Risk of cardiovascular events, stroke, congestive heart failure, interstitial lung disease, and acute liver injury: Dronedarone versus amiodarone and other Antiarrhythmics","volume":"6","author":"Gao","year":"2013","journal-title":"J Atr Fibrillation."},{"issue":"25","key":"10.1016\/j.ijcard.2024.132198_bb0150","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMoa0800456","article-title":"Increased mortality after dronedarone therapy for severe heart failure","volume":"358","author":"Kober","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ijcard.2024.132198_bb0155","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/europace\/eut293","article-title":"Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial","volume":"16","author":"Pisters","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2024.132198_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/europace\/euad083","article-title":"Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants","volume":"25","author":"Wu","year":"2023","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2024.132198_bb0165","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijcard.2018.11.133","article-title":"Impact of dronedarone on the risk of myocardial infarction and stroke in atrial fibrillation patients followed in general practices in Germany","volume":"278","author":"Ehrlich","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2024.132198_bb0170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosis.2017.09.029","article-title":"Dronedarone exerts anticoagulant and antiplatelet effects independently of its antiarrhythmic actions","volume":"266","author":"Zafar","year":"2017","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.ijcard.2024.132198_bb0175","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/CIRCULATIONAHA.106.623199","article-title":"Navigating the crossroads of coronary artery disease and heart failure","volume":"114","author":"Gheorghiade","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.132198_bb0180","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/euac062","article-title":"Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET\/EHRA consensus conference","volume":"25","author":"Schnabel","year":"2023","journal-title":"Europace"},{"issue":"11","key":"10.1016\/j.ijcard.2024.132198_bb0185","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jfma.2016.10.005","article-title":"2016 guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation","volume":"115","author":"Chiang","year":"2016","journal-title":"J. Formos. Med. Assoc."},{"issue":"5","key":"10.1016\/j.ijcard.2024.132198_bb0190","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40256-021-00483-9","article-title":"Use of flecainide in stable coronary artery disease: an analysis of its safety in both nonobstructive and obstructive coronary artery disease","volume":"21","author":"Ashraf","year":"2021","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"7 Pt 2","key":"10.1016\/j.ijcard.2024.132198_bb0195","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jacep.2022.12.021","article-title":"The feasibility and safety of flecainide use among patients with varying degrees of coronary disease","volume":"9","author":"Kiani","year":"2023","journal-title":"JACC Clin Electrophysiol."}],"updated-by":[{"DOI":"10.1016\/j.ijcard.2024.132257","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T00:00:00Z","timestamp":1726358400000}}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324008209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324008209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T20:15:28Z","timestamp":1719000928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324008209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":39,"alternative-id":["S0167527324008209"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132198","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ijcard.2024.132257","asserted-by":"object"}]},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of antiarrhythmic medications on the risk of cardiovascular outcomes in patients with atrial fibrillation and coronary artery disease","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132198","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"132198"}}